Effects of quercetin on blood pressure and endothelial function in subjects with a high CVD risk phenotype (clinical intervention study)

Effects of quercetin on blood pressure and endothelial function in subjects with a high CVD risk phenotype (clinical intervention study) - QuerEndoRR

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00000555

Enrollment

Registered

2010-12-22

Start date

2011-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrom overweight/obesity, hypertension, dyslipidaemia

Interventions

Group 1: placebo (hart gelatine capsules

duration of supplementation: 6 weeks

0 mg quercetin

intake: 0-0-0 oral with each principal meal): 3-week wash-out period between both supplementation periods Group 2: quercetin (hart gelatine capsules

150 mg/day quercetin

intake: 50-50-50 mg oral with each principal meal): 3-week wash-out period between both supplementation periods

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: overweight or obesity (BMI 25-35 kg/m2), abdominal fat distribution, elevated resting blood pressure (pre-hypertension, stadium 1 hypertension), elevated C-reactive protein (>2,0 mg/L), dyslipidemia

Exclusion criteria

Exclusion criteria: pregnancy, lactation, malabsorption syndromes, abnormal thyroid function, abnormal kidney function, secondary hypertension, liver diseases, heart failure, history of myocardial infarction, insulin-dependent diabetes mellitus, diabetes insipidus, chronic inflammatory diseases, intake of supplements (fatty acids, vitamin E, magnesium, flavonoids), alcohol abuse

Design outcomes

Primary

Measure	Time frame
Systolic and diastolic blood pressure; measurement at the beginning of the study, after 3 and after 6 weeks; measurement at the upper arm with a validated blood pressure instrument according to the method of Riva Rocci and Korotkow	—

Secondary

Measure	Time frame
Endothelial function (measurement with Endo-PAT), parameter of oxidation (oxidized LDL, F2 isoprostanes), parameter of inflammation (CRP, endothelial adhesion molecules), parameter of lipid (triglycerides, cholesterol, LDL-, HDL-cholesterol) and glucose metabolism (glucose, insulin), plasma quercetin concentration; measurement of the secondary outcomes at the beginning of the study and after 6-week of supplementation	—

Measure

Time frame

Endothelial function (measurement with Endo-PAT), parameter of oxidation (oxidized LDL, F2 isoprostanes), parameter of inflammation (CRP, endothelial adhesion molecules), parameter of lipid (triglycerides, cholesterol, LDL-, HDL-cholesterol) and glucose metabolism (glucose, insulin), plasma quercetin concentration; measurement of the secondary outcomes at the beginning of the study and after 6-week of supplementation

—

Countries

Germany

Contacts

Public ContactSarah Egert

Universität Bonn IEL Ernährungsphysiologie

s.egert@uni-bonn.de0228 / 73 3748

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026